Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJAUWG)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Rho-associated protein kinase 2 (ROCK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belumosudil	DM548TK	Graft-versus-host disease	4B24	Approved	[2]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[3]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[4]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-6	DM5RCBV	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-2	DM9ZXOP	N. A.	N. A.	Patented	[1]
Tricyclic compound 7	DME84S5	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[5]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[6]
H-1152	DM8XH3S	Pulmonary arterial hypertension	BB01.0	Phase 2	[7]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[3]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[4]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[1]
PMID28048944-Compound-6	DM5RCBV	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[1]
Rho-associated protein kinase 2 (ROCK2)	TTGWKQJ	ROCK2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
2	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
5	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
6	The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
7	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.